Publication:
Differences in cancer-specific mortality after trimodal therapy for T2N0M0 bladder cancer according to histological subtype

Placeholder

Departments

School / College / Institute

Organizational Unit

Program

KU-Authors

KU Authors

Co-Authors

Barletta,Francesco
Tappero,Stefano
Panunzio,Andrea
Incesu,Reha-Baris
Garcia,Cristina Cano
Piccinelli,Mattia Luca
Tian,Zhe
Gandaglia,Giorgio
Moschini,Marco
Terrone,Carlo

Publication Date

Language

Embargo Status

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

Simple Summary Trimodal therapy represents an accepted treatment option for non-metastatic muscle-invasive bladder cancer, which is an alternative to radical cystectomy. Evidence regarding trimodal therapy efficacy has predominantly, or even exclusively, been applied to urothelial carcinoma of the urinary bladder patients. To address this void, we tested for differences in cancer-specific mortality in trimodal therapy-treated bladder cancer patients, according to histological subtype, namely urothelial carcinoma vs. neuroendocrine carcinoma vs. squamous cell carcinoma vs. adenocarcinoma. We aimed at assessing the impact of non-urothelial variant histology (VH), relative to urothelial carcinoma of the urinary bladder (UCUB), on cancer-specific mortality (CSM) in T2N0M0 bladder cancer patients treated with trimodal therapy (TMT). TMT patients treated for T2N0M0 bladder cancer were identified within the Surveillance, Epidemiology, and End Results database (2000-2018). Patients who underwent TMT received trans-urethral resection of the bladder tumor, chemotherapy, and radiotherapy. CSM-FS rates were tested using Kaplan-Meier plots and multivariable Cox-regression (MCR) models according to histological subtype: UCUB vs. neuroendocrine carcinoma vs. squamous cell carcinoma vs. adenocarcinoma. A total of 3846 T2N0MO bladder cancer patients treated with TMT were identified. Of these, 3627 (94.3%) harbored UCUB, while 105 (2.7%), 85 (2.2%), and 29 (0.8%) harbored neuroendocrine carcinoma, squamous cell carcinoma, and adenocarcinoma, respectively. In Kaplan-Meier analyses, 3-yr CSM-FS rates were 57% for UCUB, 51% for neuroendocrine carcinoma, 35% for squamous cell carcinoma, and 60% for adenocarcinoma (p-value < 0.0001). In MCR models, only squamous cell carcinoma exhibited higher CSM than UCUB (HR 1.98, 95%CI 1.5-2.61, p-value < 0.001). Despite the small number of observations, squamous cell carcinoma distinguished itself from UCUB based on worse survival in T2N0M0 patients after TMT.

Source

Publisher

Multidisciplinary Digital Publishing Institute

Subject

Oncology

Citation

Has Part

Source

Cancers

Book Series Title

Edition

DOI

10.3390/cancers14235766

item.page.datauri

Link

Rights

Copyrights Note

Endorsement

Review

Supplemented By

Referenced By

0

Views

0

Downloads

View PlumX Details